Seattle Genetics wins FDA approval for cancer drug that could push U.S. sales past $1 billion

“This marks the first time in four decades and 10 different attempts to replace one of most toxic drugs ... for late-stage classical Hodgkin while increasing long-term survival,” founder and CEO Clay Siegall said.

Source: bizjournals.com Health Care:Biotechnology headlines - March 26, 2018 Category: Biotechnology Authors: Casey Coombs Source Type: news